Monday (24.10.2022)

07:30 – 09:00

Room: Großer Saal

Scientific Session Advanced Stages

  • Olivier Casasnovas
  • John Radford
  • 07:30–07:35

    Why I recommend BV-AVD

    • Ranjana Advani
  • 07:35–07:40

    Why I recommend PET-guided ABVD

    • Alexander Fosså
  • 07:40–07:45

    Why I recommend PET-adapted escalated BEACOPP

    • Peter Borchmann
  • 07:45–08:30

    Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

    • Martin Dreyling
    • Jack Richardson
    • Sarah Wells
  • 08:30–08:35

    WS Report: Learning through International Collaboration

    • Peter Borchmann
    • Alison Moskowitz
  • 08:35–08:47

    FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

    • Wouter Plattel
  • 08:47–09:00

    Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

    • Peter Borchmann

09:15 – 10:15

Room: Großer Saal

Scientific Session Special Situations in HL

  • Richard Hoppe
  • Marie Jose Kersten
  • 09:15–09:35

    HL in Pregnancy

    • Daan Dierickx
  • 09:35–09:55

    HIV-positive HL

    • Otavio Baiocchi
  • 09:55–10:15

    alloSCT in the era of anti-PD1

    • Anna Sureda

10:30 – 12:00

Room: Großer Saal

Scientific Session Genomics, Biology and Microenvironment

  • Wolfram Klapper
  • Ralf Küppers
  • 10:30–10:53

    Biological Classification of HL by Liquid Biopsy

    • Sven Borchmann
  • 10:53–11:16

    Single Cell Transcriptomics of HL

    • Christian Steidl
  • WS Report: Bringing Liquid Biopsy to Patients

    • Sven Borchmann
    • Davide Rossi
  • Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

    • Kristiina Karihtala
  • High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

    • Arjan Diepstra
  • Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

    • Julia Paczkowska

12:15 – 13:45

Room: Großer Saal

Satellite Symposium (by Takeda) Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

  • Graham Collins
  • Alex Herrera
  • Pier Luigi Zinzani
  • 12:15–12:20

    Welcome and introduction

    • Graham Collins
  • 12:20–12:30

    Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1

    • Graham Collins
  • 12:30–13:30

    Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)

    • Graham Collins
    • Alex Herrera
    • Pier Luigi Zinzani
  • 13:30–13:40

    Audience Q&A

  • 13:40–13:45

    Summary and close

    • Graham Collins

14:00 – 15:30

Room: Großer Saal

Scientific Session Relapsed / Refractory HL

  • Ranjana Advani
  • Craig H. Moskowitz
  • 14:00–14:23

    1ˢᵗ Relapse of HL

    • Craig H. Moskowitz
  • 14:23–14:46

    Novel developments in R/R HL

    • Graham Collins
  • 14:46–14:51

    WS Report: PET beyond Deauville

    • Sally Barrington
    • Martin Hutchings
    • Carsten Kobe
  • 14:51–15:04

    Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

    • Anna Sureda
  • 15:04–15:17

    High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

    • Alison Moskowitz
  • 15:17–15:30

    Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

    • Catherine Diefenbach

15:30 – 16:00

Room: Großer Saal

Main Program Closing Remarks

  • 15:30–16:00

    Conference Highlights

    • Ranjana Advani

16:00 – 16:30

Room: Foyer (First Floor)

Main Program Farewell

ISHL12 Program at a Glance (PDF)

ISHL12 Program at a Glance (PDF)

ISHL12 Final Program

ISHL12 Final Program